Uni-Bio Science Group Limited (HKG:0690)

Market Cap	597.12M +37.0%
Revenue (ttm)	586.21M +6.0%
Net Income	93.33M +12.7%
EPS	0.02 +15.7%
Shares Out	5.97B
PE Ratio	6.41
Forward PE	n/a
Dividend	0.00 (3.13%)
Ex-Dividend Date	May 28, 2026

Volume	1,728,000
Average Volume	7,112,275
Open	0.1010
Previous Close	0.1000
Day's Range	0.0990 - 0.1010
52-Week Range	0.0650 - 0.1680
Beta	0.01
RSI	41.54
Earnings Date	Mar 27, 2026

About Uni-Bio Science Group

Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in the People’s Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 504
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0690

Financial Performance

In 2025, Uni-Bio Science Group's revenue was 586.21 million, an increase of 6.01% compared to the previous year's 552.98 million. Earnings were 93.33 million, an increase of 12.75%.